A patient's eye view of radiation therapy: This is what it feels like
Although it can also be a robust part of curative treatment for a range of cancers (including prostate and breast cancers), in my case, it quickly — and disappointingly — became clear that radiation wasn't going to jolt my metastatic Ewing's sarcoma into retirement (never the likeliest outcome). But it ameliorated some discomforts and with notably less wear and tear than the chemo alternatives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Cowboys owner Jerry Jones said he survived a stage 4 cancer battle that lasted more than a decade
Jerry Jones sometimes says too much about his Dallas Cowboys. His cancer battle for more than a decade remained a secret though. Jones told the Dallas Morning News that he beat stage 4 melanoma. The Cowboys owner's battle lasted more than a decade, he said, and included four surgeries. "I now have no tumors," Jones, who is 82 years old, told the Dallas Morning News. Jones told the Dallas Morning News the initial diagnosis came in 2010. Over the next 10 years he had four surgeries, two on his lungs and two on his lymph nodes. He credited the experimental drug PD-1 — short for Programmed Cell Death Protein 1 — for his recovery. 'I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy],' Jones said, via the Morning News. 'I went into trials for that PD-1 and it has been one of the great medicines." In an episode of the soon to be released Netflix series "America's Team: The Gambler and His Cowboys," Jones mentioned having cancer treatments, leading the Dallas Morning News to ask him about it in an interview. Jones is the NFL's most visible owner, and his Cowboys are the most valuable sports franchise in the world. They're the first sports team to pass the $10 billion mark in Forbes' annual survey. In 2017 — when, according to Jones, he was still fighting stage 4 cancer — he was inducted into the Pro Football Hall of Fame. Jones has no problem seeking out the media for attention on practically any matters regarding his team. But his long battle against cancer was out of the spotlight, until now.
Medscape
14 minutes ago
- Medscape
A Nurse in Every School?
As a school nurse, Traci Jones, RN, PhD, NCSN, handed out ice packs and bandages, but she also helped students manage chronic health conditions ranging from diabetes and asthma to seizure disorders and life-threatening allergies. 'There can't be an expectation that the teachers know how to identify healthcare issues,' said Jones, a school nurse administrator in Temple Hills, Maryland. '[There should be] a nurse in every school.' School nurses oversee case management, assist with individualized education plans for students with disabilities; implement public health strategies for immunizations, natural disasters, and school violence; and connect families with community health resources. Despite the essential role that school nurses play in ensuring the safety and well-being of schoolchildren, a growing number of districts do not have enough nurses to meet student needs. Data from the National Association of School Nurses (NASN) found that just 65% of schools had access to a registered nurse (RN), licensed practical nurse (LPN), or licensed vocational nurse. About Medscape Data Medscape continually surveys physicians and other medical professionals about key practice challenges and current issues, creating high-impact analyses. For example, the Medscape RN/LPN Job Market Report 2025 found that Both RNs and LPNs younger than 45 years were slightly more motivated to job search than older nurses. About 6 in 10 RNs and LPNs checked out a potential new job within the past 3 years. About 1 in 6 nurses don't think they have much negotiating power when it comes to getting a new job offer. Although 20 states, including Connecticut, Delaware, Massachusetts, and Minnesota, require K-12 schools to have a school nurse, students in other states often lack access to healthcare in school. Rural areas and districts in the Midwest and West employed the fewest number of school nurses, according to NASN. The Nurses for Under-Resourced Schools Everywhere (NURSE) Act was recently reintroduced in an effort to increase healthcare access in education. The legislation aims to establish a federal grant program to help Title I schools where at least 20% of students are enrolled in free- or reduced-price breakfast and lunch programs to hire and retain school nurses. 'The NURSE Act recognizes the critical role of school nurses in providing students with access to quality healthcare so they can be healthy, safe, and ready to learn,' explained NASN president-elect Pat Endsley, PhD, RN, NCSN, FNASN. More Than Bandages and Ice Packs Injuries, illnesses, and disabilities lead to chronic school absences for almost 6% of school-aged children, and school nurses can help manage acute and chronic illnesses that are linked with poor attendance. In schools without a school nurse, 18% of students were sent home for illnesses or injuries compared with just 5% of students in schools with a school nurse. School nurses don't just affect absenteeism. Studies have found that students with access to school nurses experience better management of chronic conditions and improved academic outcomes, too. 'Sometimes we're just that place where students can come for some reassurance…Sometimes they just need 5 minutes to come in and decompress before going back to class,' Endsley said. 'We're a safe place [and] our goal is getting that student back to class and getting the most out of their education.' However, providing healthcare and safe spaces in schools comes at a cost. On average, the cost of having an LPN in a school nursing program was $115,707 per school year at a time when US schools are facing their biggest budget crunch in years. Funding for school nurses comes from a patchwork of sources, including the federal Department of Education, Medicaid, state health departments, and grants. The patchwork approach leads to disparities in resources between states and even among school districts. Cuts to Medicaid and uncertainty about the future of the Board of Education could also affect the number of nurses in schools today. The expiration of Elementary and Secondary School Emergency Relief funding allocated during the COVID-19 pandemic led to severe implications in school districts that included job cuts and loss of critical programming, including the loss of school nurses. 'Schools got COVID funds to hire a lot of school nurses, but…after those funds expired, not very many schools made those positions permanent,' said Endsley. While previous recommendations from organizations like the American Academy of Pediatrics suggested a ratio of one school nurse for every 750 students, it's considered an outdated standard, according to Endsley. Instead, she believes districts should conduct ongoing assessments to determine student needs and inform hiring decisions. A school with 500 students but few chronic health conditions might need just one school nurse, while a less populated school with a higher proportion of students with ongoing medical needs might need two (or more) nurses, she explained. But there is more to addressing the school nurse shortage than coming up with student-to-nurse ratios. Changing Perceptions Hiring school nurses is challenging. Misconceptions about the role of school nurses and burnout are among the biggest reasons that 50% of RNs and LPNs leave school nursing in 3-6 months. 'Most people don't know what school nurses do,' said Jones. 'I've had people tell me, 'You sit at the desk all day and hand out candy.'' The perception that school nursing is all about 'Band-Aids, ice, and lice' prevents school nurses from entering the profession — but the RNs who work in school settings appreciate some of the perks: There are no weekend, rotating, or overnight shifts, and many school nurses work 10 months of the year, leading to better work-life balance. There are challenges, too. School nurses experience significant pay disparities. NASN data show that just 34% of school nurses make more than $60,000 per year compared with almost 70% of the total RN workforce. This often forces school nurses to pick up additional shifts in hospitals and clinics, Jones added. The workforce also tends to be older — more than two-thirds of school nurses are over 40 — and retire sooner, leading to greater turnover. The role is also best suited to mid-career nurses. Jones calls it 'grassroots nursing.' 'You have blood pressure cuffs and a stethoscope, and your own knowledge, judgment and skill set,' she added. 'You're usually the only medical expert in the building, and you need a solid foundation.' However, when RNs work in schools, sick and injured students aren't the only ones who benefit. Schools with full-time nurses receive an average return on investment of $1.59 for every dollar invested as well as significant savings in teacher, secretary, principal, and parent productivity — and the community benefits, too. 'School nurses really are an integral part of the whole education system,' Endsley said. 'We work in partnership with our school community, with our teachers, our administrators, but also with the community at large.'
